Potent angiogenic inhibition effects of deacetylated chitohexaose separated from chitooligosaccharides and its mechanism of action in vitro.

Abstract

This study was performed to demonstrate the effects of deacetylated chitohexaose (hexamer) separated from a chitooligosaccharide (COS) mixture on tumor angiogenesis and its mechanism of action. Five fractions from dimer to hexamer were separated by a linear gradient solution of HCl on a cation-exchange resin. Then HCl was removed from the fractions by a charcoal column. The purity of the five fractions was analyzed by HPLC and the molecular masses were analyzed by MALDI-TOFMS. The hexamer expressed an inhibitory influence on CAM angiogenesis in a dose-dependent manner at concentrations of 6.25-50microg/egg. On further investigation, we found that the hexamer had no toxic effect on normal ECV304 cells, but could inhibit the proliferation and migration of tumor-induced ECV304 cells in a dose-dependent manner. The mechanism was demonstrated through the detection of mRNA expression of VEGF, MMP-9, TIMP-1, TIMP-2, and uPA by RT-PCR, which showed that the hexamer down-regulated the VEGF and uPA mRNA expressions in ECV304 cells, but up-regulated the TIMP-1 mRNA expression.

• Authors: Chuannan Xiong, Haige Wu, Peng Wei, Ma Pan, Yaqin Tuo, Isao Kusakabe, Yuguang Du
• Journal: Carbohydrate research (Carbohydr Res) Vol. 344 Issue 15 Pg. 1975-83 (Oct 12 2009) ISSN: 1873-426X [Electronic] Netherlands
• PMID: 19631932 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Oligosaccharides
• Tissue Inhibitor of Metalloproteinase-1
• Vascular Endothelial Growth Factor A
• Tissue Inhibitor of Metalloproteinase-2
• chitohexaose
• Chitosan
• Urokinase-Type Plasminogen Activator
• Matrix Metalloproteinase 9

Topics

• Cell Line
• Cell Movement (drug effects)
• Cell Proliferation (drug effects)
• Chitosan (chemistry)
• Chromatography, High Pressure Liquid
• Gene Expression (drug effects)
• Humans
• Matrix Metalloproteinase 9 (genetics)
• Molecular Structure
• Neovascularization, Physiologic (drug effects)
• Oligosaccharides (chemistry, pharmacology)
• Reverse Transcriptase Polymerase Chain Reaction
• Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
• Tissue Inhibitor of Metalloproteinase-1 (genetics)
• Tissue Inhibitor of Metalloproteinase-2 (genetics)
• Urokinase-Type Plasminogen Activator (genetics)
• Vascular Endothelial Growth Factor A (genetics)